The University Of Texas MD Anderson Cancer Center
The University Of Texas MD Anderson Cancer Center is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa, open-label, dose finding, safety, tolerability and exploratory trial of THEO-260 in patients with high grade serous or endometrioid ovarian cancer
Sponsor Theolytics Limited
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 1/2, first-in-human study on ODM-212 in subjects with selected advanced solid tumours
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) / NEPTUNE-17.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A multicentre randomized, double-blind, placebo-controlled, dose-finding, Phase 2 study (MARS-17) of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for The University Of Texas MD Anderson Cancer Center?
The 2026-10-09 snapshot links The University Of Texas MD Anderson Cancer Center to 7 distinct CTIS trials. Recorded services include BPI-SF PRO licence, Laboratory services, Copyright holder for patient questionnaire, Eligibility Confirmation, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for The University Of Texas MD Anderson Cancer Center?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to The University Of Texas MD Anderson Cancer Center conducted?
The linked trials record locations in 7 countries, including Spain, France, Germany, Denmark, Finland. These are trial locations, not confirmed office locations or countries where The University Of Texas MD Anderson Cancer Center delivered services.
What can this page tell me about The University Of Texas MD Anderson Cancer Center's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under The University Of Texas MD Anderson Cancer Center. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- The University Of Texas MD Anderson Cancer Center
- The University of Texas MD Anderson Cancer Center